The reduction in the number of attacks in multiple sclerosis patients

A clinical trial to compare the effectiveness of dimethyl fumarate in multiple sclerosis patients before and after intervention.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190121042439N1

Enrollment

Registered

2019-02-02

Start date

2019-02-20

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis patients. Multiple sclerosis

Interventions

Intervention group: The intervention group will receive 240 mg dimethyl fumarate twice a day for one year..

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with relapsing-remitting multiple sclerosis

Exclusion criteria

Exclusion criteria: History of blood diseases Liver failure Discontinuation of treatment cause of disruption in laboratory tests

Design outcomes

Primary

Measure	Time frame
Number and severity of attacks. Timepoint: Before and one year after intervention. Method of measurement: Expanded disability status scale (EDSS) score.	—

Secondary

Measure	Time frame
The number of magnetic resonance imaging (MRI) lesions. Timepoint: Before and one year after intervention. Method of measurement: Brain MRI.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSahar Gazeran

Mashhad University of Medical Sciences

Gazerans941@mums.ac.ir+98 51 3854 3031

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 19, 2026